Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • AV Rheum
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In
  • Log Out

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
  • Log Out
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • AV Rheum
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
Abstract

Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis.

Karim Raza, Mike Breese, Peter Nightingale, Kanta Kumar, Tanya Potter, David M Carruthers, Deva Situnayake, Caroline Gordon, Christopher D Buckley, Mike Salmon and George D Kitas
The Journal of Rheumatology February 2005, 32 (2) 231-238;
Karim Raza
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mike Breese
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Nightingale
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kanta Kumar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tanya Potter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David M Carruthers
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deva Situnayake
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Gordon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher D Buckley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mike Salmon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George D Kitas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

OBJECTIVE: To study the prognostic value of antibodies to cyclic citrullinated peptide (anti-CCP) and rheumatoid factor (RF), alone and in combination, in patients with very early synovitis. METHODS: A cross-sectional study was performed in patients with established inflammatory and noninflammatory disease to validate the assay in our unit and confirm previously reported sensitivities and specificities of anti-CCP antibodies. Subsequently, patients with synovitis of 3 months' duration were followed for 72 weeks and the ability of anti-CCP antibodies and RF to predict the development of rheumatoid arthritis (RA) and persistent inflammatory arthritis was assessed. RESULTS: One hundred twenty-four patients were assessed in the initial cross-sectional study. Anti-CCP antibodies and RF were detected by ELISA in only 4% of patients with non-RA inflammatory disease and in no patient with noninflammatory disease. Ninety-six patients with very early synovitis were assessed longitudinally. In these patients with early arthritis, the combination of anti-CCP antibodies and RF had a specificity, positive predictive value (PPV), sensitivity, and negative predictive value (NPV) for a diagnosis of RA of 100%, 100%, 58%, and 88%, respectively. The specificity, PPV, sensitivity, and NPV of this antibody combination for the development of persistent disease-fulfilling classification criteria for RA were 97%, 86%, 63%, and 91%, respectively. CONCLUSION: In patients with synovitis of 3 months' duration, a combination of anti-CCP antibodies and RF has a high specificity and PPV for the development of persistent RA. This autoantibody combination can be used to identify patients with disease destined to develop RA who may be appropriate for very early intervention.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 32, Issue 2
1 Feb 2005
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis.
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
Citation Tools
Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis.
Karim Raza, Mike Breese, Peter Nightingale, Kanta Kumar, Tanya Potter, David M Carruthers, Deva Situnayake, Caroline Gordon, Christopher D Buckley, Mike Salmon, George D Kitas
The Journal of Rheumatology Feb 2005, 32 (2) 231-238;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis.
Karim Raza, Mike Breese, Peter Nightingale, Kanta Kumar, Tanya Potter, David M Carruthers, Deva Situnayake, Caroline Gordon, Christopher D Buckley, Mike Salmon, George D Kitas
The Journal of Rheumatology Feb 2005, 32 (2) 231-238;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • AV Rheum

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire